STEPHEN G SAWADA, M.D.
Osteopathic Medicine at Senate Blvd, Indianapolis, IN
License number
Indiana 01037079A
Category
Osteopathic Medicine
Type
Clinical Cardiac Electrophysiology
License number
Indiana 01037079A
Category
Osteopathic Medicine
Type
Critical Care Medicine
License number
Indiana 01037079
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
1801 N Senate Blvd, Indianapolis, IN 46202
Phone
(317) 962-0533
Personal information
See more information about STEPHEN G SAWADA at radaris.comName
Address
Phone
4391 Brittany Dr, Zionsville, IN 46077
4834 Quail Crescent Ct, Indianapolis, IN 46254
Zionsville, IN
4391 Brittany Dr, Zionsville, IN 46077
4834 Quail Crescent Ct, Indianapolis, IN 46254
Organization information
See more information about STEPHEN G SAWADA at bizstanding.comI U Health Physicians Cardiology - Stephen G Sawada MD
1801 Senate Blvd STE 4000, Indianapolis, IN 46202
Categories:
Cardiology Physicians & Surgeons, Internal Medicine Physicians & Surgeons
Phone:
(317) 962-0500 (Phone)
Professional information
See more information about STEPHEN G SAWADA at trustoria.com
Dr. Stephen G Sawada, Indianapolis IN - MD (Doctor of Medicine)
Dr. Stephen G Sawada, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
Krannert Institute Cardiology
1801 Senate Blvd SUITE 4000, Indianapolis 46202
(317) 962-0500 (Phone)
1801 Senate Blvd SUITE 4000, Indianapolis 46202
(317) 962-0500 (Phone)
Procedures:
Ablation for Treatment of Cardiac Arrythmias, Cardiac Catheterization (incl. Coronary Angiography), Cardiac Imaging, Cardiac Myocardial Perfusion Imaging, Cardioversion, Elective, Coronary Angioplasty, Atherectomy and Stent, Peripheral Artery Catheterization, Thoracentesis
Conditions:
Aneurysm and Dissection of Heart, Angina and Acute Coronary Syndrome, Aortic Aneurysm, Aortic Dissection, Aortic Valve Disease, Arrhythmias (incl. Atrial Fibrillation), Cardiomegaly, Cardiomyopathy, Coarctation of the Aorta, Congenital Heart Disease, Congestive Heart Failure, Coronary Artery Disease (CAD), Endocarditis, Heart Attack (Acute Myocardial Infarction), Hyperlipidemia, Hypertension, Hypertensive Heart and Chronic Kidney Disease, Hypertensive Heart Disease, Hypotension, Marfan Syndrome, Mitral Valve Disease, Pericardial Disease, Pulmonary Hypertension, Pulmonary Valve Disease, Septal Defect, Syncope, Tricuspid Valve Disease
Certifications:
Cardiovascular Disease, 1987, Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Krannert Institute Cardiology
1801 Senate Blvd SUITE 4000, Indianapolis 46202
Hendricks Regional Health
1000 East Main St, Danville 46122
Community Hospital North
7150 Clearvista Dr, Indianapolis 46256
1801 Senate Blvd SUITE 4000, Indianapolis 46202
Hendricks Regional Health
1000 East Main St, Danville 46122
Community Hospital North
7150 Clearvista Dr, Indianapolis 46256
Education:
Medical School
University Of Rochester School Of Medicine and Dentistry
Graduated: 1982
University Rochester
Graduated: 1985
Indiana University
Graduated: 1988
St Mary Med Center
Graduated: 1987
University Of Rochester School Of Medicine and Dentistry
Graduated: 1982
University Rochester
Graduated: 1985
Indiana University
Graduated: 1988
St Mary Med Center
Graduated: 1987
Method For Determining Viability Of A Myocardial Segment
Method For Determining Viability Of A Myocardial Segment
US Patent:
6339716, Jan 15, 2002
Filed:
Sep 24, 1999
Appl. No.:
09/405462
Inventors:
Stephen G. Sawada - Indianapolis IN
John St. Cyr - Coon Rapids MN
Clarence A. Johnson - Wyoming MN
John St. Cyr - Coon Rapids MN
Clarence A. Johnson - Wyoming MN
Assignee:
Bioenergy Inc. - Ham Lake MN
International Classification:
A61B 505
US Classification:
600407, 600425, 600436, 600365, 600476, 600479, 600450, 600449
Abstract:
A method of determining the viability of a hibernating or stunned myocardial segment comprises the administration of ribose, a vasodilator and an inotropic agent. The preferred agent is dobutamine, which has both a vasodilation and an inotropic effect. The segments may be identified by myocardial imaging by any known means, such as echocardiography, Thallium-201 tracing or positron emission tomography. Ribose is preferably given one minute to three hours prior to administration of the vasodilator and inotropic agents.
Method For Raising The Hypoxic Threshold
Method For Raising The Hypoxic Threshold
US Patent:
6218366, Apr 17, 2001
Filed:
Sep 24, 1999
Appl. No.:
9/406266
Inventors:
John St. Cyr - Coon Rapids MN
Clarence A. Johnson - Wyoming MN
Dean J. MacCarter - Englewood CO
Stephen G. Sawada - Indianapolis IN
Clarence A. Johnson - Wyoming MN
Dean J. MacCarter - Englewood CO
Stephen G. Sawada - Indianapolis IN
Assignee:
Bioenergy, Inc. - Ham Lake MN
International Classification:
A61K 3170
US Classification:
514 23
Abstract:
The administration of ribose raises the hypoxic threshold of mammals experiencing a hypoxic condition. The presence of an effective amount of ribose in the tissue of a mammal increases the tolerance to hypoxia and decreases the symptoms of hypoxia in mammals experiencing chronic hypoxia due to cardiovascular disease or peripheral vascular disease. Such mammals are additionally benefited by administration of ribose and a vasodilator or an isotropic agent. Mammals experiencing transient hypoxia from high altitude, anesthesia or exercise are also benefited.